- Trials with a EudraCT protocol (1,892)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
1,892 result(s) found.
Displaying page 32 of 95.
EudraCT Number: 2012-005767-27 | Sponsor Protocol Number: OPN305-103 | Start Date*: 2014-01-09 | |||||||||||
Sponsor Name:Opsona Therapeutics Ltd | |||||||||||||
Full Title: Follow-up Protocol to the Double-Blind Parts A and B of the Phase II Opsona Study OPN305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Ad... | |||||||||||||
Medical condition: Prevention of Kidney Graft Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) AT (Completed) ES (Ongoing) DE (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006228-21 | Sponsor Protocol Number: GPI-06-0002 | Start Date*: 2007-05-10 | |||||||||||
Sponsor Name:Gloucester Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEM... | |||||||||||||
Medical condition: Progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) ES (Completed) SE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005539-22 | Sponsor Protocol Number: GO28076 | Start Date*: 2012-10-08 | ||||||||||||||||||||||||||
Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||
Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLA... | ||||||||||||||||||||||||||||
Medical condition: Head and neck cancer of squamous cell origin | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) HU (Completed) IT (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003738-34 | Sponsor Protocol Number: CA209-143 | Start Date*: 2014-06-05 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)... | |||||||||||||
Medical condition: Recurrent glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) ES (Completed) BE (Ongoing) DK (Completed) PL (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001646-18 | Sponsor Protocol Number: AMB115811 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) AT (Completed) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001344-11 | Sponsor Protocol Number: CCD-GPLSCD01-03-FU | Start Date*: 2018-04-11 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium i... | |||||||||||||
Medical condition: corneal lesions with associated moderate to severe limbal stem cell deficiency due to ocular burns | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) FR (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002606-20 | Sponsor Protocol Number: CV185-325/B0661037 | Start Date*: 2015-11-06 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT | |||||||||||||
Medical condition: Venous Thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) Outside EU/EEA AT (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) PT (Ongoing) IT (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001610-42 | Sponsor Protocol Number: X052130/CL3-78989-005 | Start Date*: 2013-01-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:XOMA (US) LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Non-infectious Intermediate, Posterior, or Pan- Uveitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) PT (Completed) GB (Prematurely Ended) ES (Completed) GR (Prematurely Ended) AT (Completed) PL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011128-70 | Sponsor Protocol Number: CSOM230G2304 | Start Date*: 2011-08-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, multicentre, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing’s disease | |||||||||||||
Medical condition: Cushing's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011056-21 | Sponsor Protocol Number: CRAD001L2202 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 ... | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) GB (Completed) DE (Completed) IT (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019630-28 | Sponsor Protocol Number: C10-001 | Start Date*: 2011-10-19 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIR... | |||||||||||||
Medical condition: Antibody mediated rejection after kidney transplant | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NO (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004853-18 | Sponsor Protocol Number: PTC124-GD-019-DMD | Start Date*: 2012-04-27 | ||||||||||||||||
Sponsor Name:PTC Therapeutics, Inc | ||||||||||||||||||
Full Title: An Open-Label Study for Previously Treated Ataluren (PTC124®) Patients with Nonsense Mutation Dystrophinopathy | ||||||||||||||||||
Medical condition: Nonsense mutation dystrophinopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) DE (Completed) GB (Completed) ES (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005083-28 | Sponsor Protocol Number: BAY 43-9006 / 12782 | Start Date*: 2008-02-27 | |||||||||||
Sponsor Name:Bayer Healthcare AG, Leverkusen | |||||||||||||
Full Title: Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda líne... | |||||||||||||
Medical condition: Carcinoma metastásico de células renales (Advanced renal cell cancer.) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001272-29 | Sponsor Protocol Number: BCX7353-203 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals Inc | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of BCX7353 as a preventative... | |||||||||||||
Medical condition: Hereditary Angioedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) ES (Completed) AT (Completed) DK (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003498-82 | Sponsor Protocol Number: 4429-301 | Start Date*: 2019-03-18 | |||||||||||
Sponsor Name:Acucela Inc. | |||||||||||||
Full Title: A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease | |||||||||||||
Medical condition: Stargardt Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DK (Ongoing) DE (Ongoing) ES (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004054-21 | Sponsor Protocol Number: CC-5013-DLC-002 | Start Date*: 2014-09-26 | ||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||
Full Title: Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Ch... | ||||||||||||||||||||||||||||
Medical condition: Previously untreated, activated B-cell (ABC) type diffuse large B-cell lymphoma (DLBCL). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) IE (Ongoing) CZ (Ongoing) IT (Ongoing) PT (Ongoing) BE (Ongoing) NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002267-11 | Sponsor Protocol Number: CAMN107A2201 | Start Date*: 2006-11-10 |
Sponsor Name:Novartis Pharma Services | ||
Full Title: A randomized, open-label,multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intolera... | ||
Medical condition: Gastrointestinal stromal tumors (GIST) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000880-27 | Sponsor Protocol Number: CLBH589B2201 | Start Date*: 2007-02-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma | |||||||||||||
Medical condition: Adult patients with stages IB to IVA mycosis fungoides (MF) or Sézary syndrome (SS). All patients must have received at least two prior treatment regimens for their MF or SS, at least one of whic... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) HU (Completed) BE (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006955-28 | Sponsor Protocol Number: C08-003B | Start Date*: 2009-08-19 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | |||||||||||||
Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapysensitive Atypical Hemolytic-Uremic Syndrome (aHUS). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014834-22 | Sponsor Protocol Number: CAIN457C2302 | Start Date*: 2010-07-06 | |||||||||||||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||||||||||||
Full Title: Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la induc... | |||||||||||||||||||||||
Medical condition: determinación de dosis y 28 semanas de duración, para evaluar AIN457 frente a placebo en la inducción y mantenimiento de la supresión de la uveítis en adultos con uveítis activa no infecciosa inter... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
